Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky
Leann
L
Department of Endocrinology, Cleveland Clinic, OH 44195, USA. olanskl@ccf.org
D000208:Acute Disease; D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D054795:Incretins / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D010195:Pancreatitis / Q000139:chemically induced* / Q000209:etiology; D012306:Risk; D055815:Young Adult
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D052216:Glucagon-Like Peptide 1